Belatacept and the Risk of Cytomegalovirus, BK Polyomavirus, and Epstein–Barr Virus Post‐transplant Lymphoproliferative Disease After Kidney Transplantation: A Meta‐Analysis and Systematic Review
Cybele Lara R. Abad, Raymund R. Razonable · 2026
Read Belatacept and the Risk of Cytomegalovirus, BK Polyomavirus, and Epstein–Barr Virus Post‐transplant Lymphoproliferative Disease After Kidney Transplantation: A Meta‐Analysis and Systematic Review by Cybele Lara R. Abad, Raymund R. Razonable (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13570610.txt.
Description
Cybele Lara Abad and Raymund Razonable review whether a transplant drug raises viral infection risks in this 2026 paper. Belatacept helps prevent kidney rejection, but its long-term safety record is incomplete. The team pooled sixty-four studies on three threats: two viruses and a virus-linked lymph disorder.
In randomized trials, infection risks on the drug matched those on the standard drug class. One exception appeared after year two: a stronger dose doubled one virus's infection rate. In real-world studies, two viruses showed roughly double the risk on belatacept. Reports of the lymph disorder did not rise clearly in trials. The authors caution that the real-world studies carry limits. They advise vigilance for viral infections in long-term users.
Catalog record
| CREATOR | Cybele Lara R. Abad, Raymund R. Razonable |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |